Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

BIOLOGICAL: Recombinant human hyaluronidase + immune globulin intravenous
BIOLOGICAL: Recombinant human hyaluronidase + immune globulin intravenous

Sponsor

Baxalta now part of Shire